RxSight (RXST) Change in Receivables (2020 - 2026)

RxSight (RXST) has reported Change in Receivables for 7 consecutive years, with -$3.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables fell 29.09% year-over-year to -$3.7 million; the trailing twelve-month figure through Jun 2026 stood at -$9.4 million (down 489.63% YoY), and the FY2025 full-year result was -$6.7 million, down 167.89% from the prior year.
• Change in Receivables fell to -$3.7 million in Q2 2026 per RXST's latest filing, from -$936000.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $5.0 million in Q4 2023 and bottomed at -$3.9 million in Q3 2025.
• Historically, Change in Receivables has averaged $772388.9 across 5 years, with a median of $1.1 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Change in Receivables surged 566.45% in 2024, then slumped 1120.94% in 2025.
• Over 5 years, Change in Receivables stood at $1.9 million in 2022, then soared by 160.31% to $5.0 million in 2023, then decreased by 7.05% to $4.7 million in 2024, then slumped by 116.83% to -$788000.0 in 2025, then slumped by 373.1% to -$3.7 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$3.7 million, -$936000.0, and -$788000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.